-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

330 The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results

Program: Oral and Poster Abstracts
Type: Oral
Session: 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches
Hematology Disease Topics & Pathways:
antibodies, Biological, AML, Leukemia, Diseases, Therapies, Myeloid Malignancies, stem cells
Sunday, December 6, 2020: 9:30 AM

David A. Sallman, MD1, Adam S. Asch, MD2, Suman Kambhampati, MD3*, Monzr M. Al Malki, MD4, Joshua F. Zeidner, MD5, William Donnellan, MD6, Daniel J. Lee, MD7, Paresh Vyas, MRCP, FRCP, FRCPath8, Deepa Jeyakumar, MD9, Gabriel N. Mannis, MD10, Tiffany N Tanaka, MD11, Wanxing Chai-Ho, MD12, Richard A. Larson, MD13, Andrew R. Whiteley, MD14, Guido Marcucci, MD4, Rami S. Komrokji, MD1, Guillermo Garcia-Manero, MD15, Joanna Van Elk16*, Ming Lin, PhD16*, Roy Maute, PhD16*, Jens-Peter Volkmer, MD16*, Chris H. Takimoto, MD, PhD16*, Mark P. Chao, MD, PhD16* and Naval Daver, MD15

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
3HCA Midwest Health at Research Medical Center, Kansas City, MO
4City of Hope, Duarte, CA
5Lineberger Comprehensive Cancer Center, Chapel Hill, NC
6Tennessee Oncology / Sarah Cannon Research Institute, Nashville, TN
7Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
8University of Oxford, Oxford, United Kingdom
9University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA
10Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
11Moores Cancer Center, University of California San Diego, San Diego, CA
12Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA
13Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
14Baylor University Medical Center, Dallas, TX
15MD Anderson Cancer Center, Houston, TX
16Gilead Sciences, Inc., Foster City, CA

Introduction: Magrolimab (Hu5F9-G4) is an antibody blocking CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancers. Magrolimab induces tumor phagocytosis and eliminates leukemia stem cells (LSCs). Azacitidine (AZA) synergizes with magrolimab by inducing “eat me” signals on leukemic blasts, thereby enhancing phagocytosis. Magrolimab + AZA has been shown to be clinically effective in acute myeloid leukemia (AML) and myelodysplastic syndrome. We report here updated phase 1b data of this combination in untreated AML, including TP53-mutant AML.

Methods: The phase 1b data represent treatment-naive AML patients unfit for intensive chemotherapy. A magrolimab priming/intrapatient dose-escalation regimen (1–30 mg/kg IV weekly followed by 30 mg/kg Q2W dosing in cycle 3 and beyond) was utilized to mitigate on-target anemia. AZA dosing was 75 mg/m2 on days 1–7 on a 28-day cycle. Responses were assessed by European LeukemiaNet 2017 criteria.

Results: Fifty-two AML patients with a median age of 73 years (range 31 to 89) were treated with magrolimab+AZA. The majority (64%) had poor risk cytogenetics. Further, 65% of patients had TP53 mutations, which were specifically enriched for this trial. 64% of all patients had complex cytogenetics, including 83% of TP53-mutant AML patients. Magrolimab+AZA was w­­­ell tolerated with a safety profile similar to AZA monotherapy. Treatment-related adverse events (AEs) (≥15% of patients) for magrolimab+AZA were anemia (31%), fatigue (19%), blood bilirubin increase (19%), neutropenia (19%), thrombocytopenia (17%), and nausea (15%). On-target anemia was generally transient and reversible with no observed grade 4 or 5 AEs, and 56% of AML patients became red blood cell transfusion independent on therapy. No immune-related AEs associated with magrolimab were observed. Treatment-related febrile neutropenia occurred in only 2 (3.8%) patients. Only 2 (3.8%) patients discontinued due to a treatment-related AE. Thirty-four patients were evaluable for efficacy at time of data cut. Of these patients, 22 (65%) achieved an objective response; 15 (44%) achieved complete remission (CR), 4 (12%) with CR with incomplete count recovery (CRi), 1 (3%) with partial response, 2 (6%) with morphological leukemia-free state (MLFS), 11 (32%) with stable disease (SD), and 1 (3%) with progressive disease (PD). Time to response was more rapid (median 2.04 months) than expected for AZA alone. For those with abnormal cytogenetics at baseline, 7/15 (47%) achieved a cytogenetic CR, and 7/19 (37%) of patients with CR/CRi became minimal residual disease negative by flow cytometry.

In TP53-mutant AML patients, 15/21 (71%) achieved an objective response; 10 (48%) achieved a CR, 4 (19%) with CRi, 1 (5%) with MLFS, 5 (24%) with SD, and 1 (5%) with PD. The median duration of response was 9.9 months (range 0.03+ to 15.1+ mo ongoing); 89% of patients continued in response at 6 months. The median overall survival (OS) for TP53-mutant AML patients (n=34) was 12.9 months (95% CI: 6.24 mo – not reached). The median OS for TP53 wild-type AML patients (n=16) was 18.9 months (95% CI: 4.34 mo – not reached). The median follow-up for TP53-mutant and wild-type patients was 4 and 12 months, respectively.

CD47 expression is enriched on AML LSCs, and magrolimab has demonstrated LSC targeting activity preclinically. Thus, the impact of magrolimab therapy on LSCs was evaluated. Putative bone marrow LSCs, as defined by CD34+CD38– expression, were eliminated by magrolimab+AZA in 71% of all responding AML patients. Additional correlative studies, including the impact of therapy on TP53 mutational burden and immune cell composition, are in progress.

Conclusions: Magrolimab is a novel immunotherapy and LSC-targeting agent that blocks a key macrophage checkpoint. Magrolimab+AZA is well tolerated with no immune-related AEs observed in relation to magrolimab. On-target anemia is mitigated by a priming/maintenance dose strategy. Efficacy is seen in both TP53-mutant and wild-type AML patients. While sample size and follow-up are limited, efficacy is particularly encouraging in TP53-mutant AML with a 71% response rate, 48% CR rate, and median OS of 12.9 months. Expansion cohorts in AML are ongoing (NCT03248479) and a phase 3 trial evaluating magrolimab+AZA in untreated TP53-mutant AML patients is planned. Additional patients, follow-up, and correlative studies will be reported at time of presentation.

Disclosures: Sallman: Agios, Bristol Myers Squibb, Celyad Oncology, Incyte, Intellia Therapeutics, Kite Pharma, Novartis, Syndax: Consultancy; Celgene, Jazz Pharma: Research Funding. Asch: MacroGenics: Research Funding; Juno: Research Funding; Forty Seven: Research Funding; Astellas Pharma: Research Funding; Cartesian: Research Funding; MEI Pharma: Patents & Royalties: Provisional patent submitted (I), Research Funding. Kambhampati: AbbVie: Other: Investigator in AbbVie-sponsored clinical trials.. Al Malki: Jazz Pharmacuticals, Inc: Consultancy; Neximmune: Consultancy; Rigel Pharma: Consultancy. Zeidner: Daiichi Sankyo: Honoraria; Genentech: Honoraria; Sumitomo Dainippon Pharma Oncology, Inc.: Research Funding; Pfizer: Honoraria; Takeda: Consultancy, Honoraria, Other: Travel Reimbursement, Research Funding; AsystBio Laboratories: Consultancy; AROG: Research Funding; Forty-Seven: Other: Travel Reimbursement, Research Funding; Merck: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Honoraria, Other: Independent Review Committee; Agios: Honoraria. Donnellan: Daiichi Sankyo: Research Funding; CTI Biopharma: Research Funding; Celgene: Research Funding; Bristol-Myers Squibb: Research Funding; Bellicum Pharmaceuticals: Research Funding; Pfizer: Research Funding; MedImmune: Research Funding; Kite Pharma/Gilead: Research Funding; Karyopharm Therapeutics: Research Funding; Janssen: Research Funding; Incyte: Research Funding; Forty Seven: Research Funding; Forma Therapeutics: Research Funding; H3 Biomedicine: Research Funding; Astex Pharmaceuticals: Research Funding; PTC Therapeutics: Consultancy, Research Funding; Amgen: Consultancy; Abbvie: Consultancy, Research Funding; TCR2 Therapeutics: Research Funding; Ryvu Therapeutics: Research Funding; Seattle Genetics: Consultancy, Research Funding; Genentech: Research Funding; Takeda: Research Funding; Celularity: Research Funding; AstraZeneca: Research Funding. Lee: Sumitomo Dainippon Pharma Oncology, Inc.: Research Funding; Novartis: Research Funding; Genentech: Research Funding; Forty Seven: Research Funding; Bayer: Research Funding; AbbVie: Research Funding; Celgene: Consultancy. Vyas: Pfizer: Speakers Bureau; Daiichi Sankyo: Speakers Bureau; Astellas: Speakers Bureau; AbbVie: Speakers Bureau; Novartis: Research Funding, Speakers Bureau; Forty Seven: Research Funding; Celgene: Research Funding, Speakers Bureau. Jeyakumar: Pfizer, Jazz Pharmaceuticals: Research Funding. Mannis: AbbVie, Agios, Bristol-Myers Squibb, Genentech: Consultancy; Glycomimetics, Forty Seven, Inc, Jazz Pharmaceuticals: Research Funding. Larson: Novartis, Takeda, CVS/Caremark, Celgene, Amgen, Epizyme: Consultancy; Astellas, Celgene, Daiichi Sankyo, Novartis, Rafael Pharmaceuticals, Cellectis, Forty Seven: Research Funding. Whiteley: Karyopharm: Current equity holder in publicly-traded company; Aprea: Current equity holder in publicly-traded company; Pfizer: Consultancy; Novartis: Consultancy; MorphoSys: Consultancy; Seattle Genetics: Consultancy, Speakers Bureau; Agios: Consultancy, Speakers Bureau; Dova: Consultancy; Jazz: Speakers Bureau; GlaxoSmithKline: Speakers Bureau; Epizyme: Current equity holder in publicly-traded company, Speakers Bureau; Rigel: Consultancy. Marcucci: Iaso Bio: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Merck: Other: Research Support (Investigation Initiated Clinical Trial); Takeda: Other: Research Support (Investigation Initiated Clinical Trial); Abbvie: Speakers Bureau; Pfizer: Other: Research Support (Investigation Initiated Clinical Trial). Komrokji: Geron: Honoraria; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria; Incyte: Honoraria; JAZZ: Honoraria, Speakers Bureau; Acceleron: Honoraria; AbbVie: Honoraria; Agios: Honoraria, Speakers Bureau. Garcia-Manero: H3 Biomedicine: Research Funding; Jazz Pharmaceuticals: Consultancy; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Onconova: Research Funding; Acceleron Pharmaceuticals: Consultancy, Honoraria; Amphivena Therapeutics: Research Funding; Novartis: Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding. Van Elk: Gilead Sciences, Inc.: Current Employment. Lin: Gilead Sciences, Inc.: Current Employment. Maute: Gilead Sciences, Inc.: Current Employment. Volkmer: Gilead Sciences, Inc.: Current Employment. Takimoto: Gilead Sciences, Inc.: Current Employment. Chao: Gilead Sciences: Current Employment. Daver: Bristol-Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novimmune: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Trovagene: Research Funding; Fate Therapeutics: Research Funding; ImmunoGen: Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz: Consultancy, Membership on an entity's Board of Directors or advisory committees; Trillium: Consultancy, Membership on an entity's Board of Directors or advisory committees; Syndax: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity's Board of Directors or advisory committees; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Research Funding; Servier: Research Funding; Genentech: Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH